Fig. 4From: Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)Overall survival according to anti-EGFR/anti-VEGF based therapy and TP53 mutation status in metastatic colorectal cancer. Kaplan-Meier curves for overall survival in TP53 mutant (a) or TP53 wild-type (b) disease with first-line anti-EGFR or anti-VEGF based therapy. HR is hazard ratio, 95% confidence interval in bracketsBack to article page